A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

2023-508363-79-00 Protocol ALN-APP-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 29 Jun 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol ALN-APP-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 63
Countries 1
Sites 1

Early-onset Alzheimer's disease (EOAD)

Key facts

Sponsor
Alnylam Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
29 Jun 2022 → ongoing
Decision date (initial)
2024-02-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508363-79-00
EudraCT number
2021-003198-74
ClinicalTrials.gov
NCT05231785

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Early-onset Alzheimer's disease (EOAD)

VersionLevelCodeTermSystem organ class
24.1 LLT 10086384 Early onset Alzheimer´s disease 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Alnylam Pharmaceuticals Inc.

Sponsor organisation
Alnylam Pharmaceuticals Inc.
Address
300 3rd Street
City
Cambridge
Postcode
02142-1103
Country
United States

Scientific contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Clinical Trials Information Line

Public contact point

Organisation
Alnylam Pharmaceuticals Inc.
Contact name
Clinical Trials Information Line

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 6 1
Rest of world
United States, Canada, United Kingdom
57

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Brain Research Center Amsterdam B.V.
Neurology, Cronenburg 2, 1081 GN, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2022-06-29 2024-02-05

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-25 Netherlands Acceptable
2024-02-05
2024-02-05
2 SUBSTANTIAL MODIFICATION SM-1 2024-03-25 Netherlands Acceptable with conditions
2024-07-01
2024-07-05
3 SUBSTANTIAL MODIFICATION SM-2 2025-04-25 Netherlands Acceptable
2025-07-03
2025-07-03
4 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-05 Netherlands Acceptable
2025-07-03
2026-03-05